Carr Financial Group Corp Purchases 81 Shares of Amgen Inc. (NASDAQ:AMGN)

Carr Financial Group Corp boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,189 shares of the medical research company’s stock after buying an additional 81 shares during the period. Carr Financial Group Corp’s holdings in Amgen were worth $831,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMGN. Atlas Private Wealth Advisors lifted its stake in shares of Amgen by 0.7% in the 4th quarter. Atlas Private Wealth Advisors now owns 5,665 shares of the medical research company’s stock valued at $1,476,000 after purchasing an additional 41 shares during the last quarter. Gradient Investments LLC lifted its stake in shares of Amgen by 22.5% in the 4th quarter. Gradient Investments LLC now owns 49,505 shares of the medical research company’s stock valued at $12,903,000 after purchasing an additional 9,095 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Amgen by 24.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 7,445 shares of the medical research company’s stock valued at $1,940,000 after purchasing an additional 1,464 shares during the last quarter. Berbice Capital Management LLC bought a new stake in shares of Amgen in the 4th quarter valued at approximately $198,000. Finally, Encompass More Asset Management lifted its stake in shares of Amgen by 5.7% in the 4th quarter. Encompass More Asset Management now owns 1,418 shares of the medical research company’s stock valued at $370,000 after purchasing an additional 76 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Down 0.9 %

Amgen stock opened at $275.42 on Friday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock has a market capitalization of $148.05 billion, a price-to-earnings ratio of 35.27, a PEG ratio of 2.78 and a beta of 0.56. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The business has a fifty day moving average price of $271.55 and a 200-day moving average price of $306.24.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the firm earned $4.96 EPS. Equities research analysts forecast that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. Amgen’s dividend payout ratio (DPR) is presently 121.90%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AMGN shares. Wells Fargo & Company lowered their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Piper Sandler reduced their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. UBS Group reduced their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Citigroup reduced their price target on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Finally, Sanford C. Bernstein initiated coverage on Amgen in a report on Thursday, October 17th. They set an “outperform” rating and a $380.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $314.65.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.